Semler cuts headcount 37%, reports $1.2M severance; provides Strive merger updates

This filing

the headcount reduction, which are expected to be realized beginning in January 2026. Semler Scientific currently estimates that it will incur severance costs of approximately $1.2 million consisting of one-time termination benefits, which are expected to be paid in December 2025 and January 2026. The charges Semler Scientific expects to incur in connection with

Comparable filing

As part of previously announced efforts by IO Biotech, Inc. (the “Company”) to reduce the Company’s operating expenses while the Company explores a range of strategic alternatives, the Board of Directors of the Company approved on January 21, 2026, a restructuring and workforce reduction plan (the “Plan”) which is expected to result in a significant reduction of the Company’s workforce globally. In connection with the implementation of the Plan, the Company expects to incur one-time charges and cash expenditures in a range of approximately $2.4 million to $2.6 million, primarily related to employee wages and severance payments, healthcare continuation, earned vacation time and related termination costs.

This filing

the headcount reduction, which are expected to be realized beginning in January 2026. Semler Scientific currently estimates that it will incur severance costs of approximately $1.2 million consisting of one-time termination benefits, which are expected to be paid in December 2025 and January 2026. The charges Semler Scientific expects to incur in connection with

Comparable filing

efficiencies and streamlined operations. We expect the reduction in force to result in annual cost savings of $6 million to $8 million. Restructuring charges of approximately $3 million are expected to be recognized in the third and fourth quarters of fiscal 2026 and primarily consist of cash charges for employee termination benefits. We expect the workforce

This filing

the headcount reduction, which are expected to be realized beginning in January 2026. Semler Scientific currently estimates that it will incur severance costs of approximately $1.2 million consisting of one-time termination benefits, which are expected to be paid in December 2025 and January 2026. The charges Semler Scientific expects to incur in connection with

Comparable filing

Plan as well as savings related to certain restricted stock units lapsing over the next twelve months. The Company estimates that it will incur pre-tax charges in the range of $0.14 million to $0.20 million in connection with the Plan, consisting of approximately $0.10 to $0.15 in future cash-based expenditures associated with severance and benefit payments and

This filing

the headcount reduction, which are expected to be realized beginning in January 2026. Semler Scientific currently estimates that it will incur severance costs of approximately $1.2 million consisting of one-time termination benefits, which are expected to be paid in December 2025 and January 2026. The charges Semler Scientific expects to incur in connection with

Comparable filing

Item 2.05 Costs Associated with Exit or Disposal Activities. On April 29, 2026, Autolus Therapeutics plc (the “Company”) announced its Board of Directors approved a plan to improve operational efficiency and reduce operating expenses. This plan will implement a reduction in force whereby the Company will eliminate approximately 13% of the Company’s workforce, inclusive of employee-related actions that began in the second half of 2025. The Company anticipates that it will complete the implementation of the plan by the third quarter of 2026. Affected employees will be offered separation benefits, including severance payments and, where applicable, temporary healthcare coverage assistance. The Company estimates that it will incur total expenses relating to the realignment of approximately $8 million, consisting of severance and termination-related costs. The Company expects to record a significant portion of these charges in the first half of 2026.

This filing

the headcount reduction, which are expected to be realized beginning in January 2026. Semler Scientific currently estimates that it will incur severance costs of approximately $1.2 million consisting of one-time termination benefits, which are expected to be paid in December 2025 and January 2026. The charges Semler Scientific expects to incur in connection with

Comparable filing

Ahead of its name change to "People Incorporated" which is expected to occur with the release of Q2 2026 earnings in August, the Company has initiated a plan to consolidate its corporate functions with those of its People Inc. business (" People "), through a reduction in workforce, technology integrations, and other cost-saving measures over the coming quarters (the " Plan "). The Plan is expected to generate annual run-rate cost savings of approximately $40 million. The Plan is expected to be completed by Q1 of 2027. The Company expects to incur approximately $14 million in severance and related expenses, $48 million in non-cash stock-based compensation expense and $0.5 million to $1 million in other costs related to the Plan.

This filing

the headcount reduction, which are expected to be realized beginning in January 2026. Semler Scientific currently estimates that it will incur severance costs of approximately $1.2 million consisting of one-time termination benefits, which are expected to be paid in December 2025 and January 2026. The charges Semler Scientific expects to incur in connection with

Comparable filing

increased operational efficiencies to accelerate our path toward net-income profitability. As a result, we currently estimate that we will incur pre-tax charges in the range of $95 million to $130 million, primarily consisting of severance and related costs, contract termination costs, and other impairment charges, of which $75 million to $100 million are expected

This filing

the headcount reduction, which are expected to be realized beginning in January 2026. Semler Scientific currently estimates that it will incur severance costs of approximately $1.2 million consisting of one-time termination benefits, which are expected to be paid in December 2025 and January 2026. The charges Semler Scientific expects to incur in connection with

Comparable filing

On April 9, 2026, the Company also announced a cost reduction program that includes a reduction in the Company’s workforce of approximately 11% of its full-time roles, including certain management roles and two executive roles. In connection with this workforce reduction, the Company expects to incur aggregate charges of approximately $8.5-$9 million, consisting primarily of employee-related costs, including severance, benefits, and other related expenses.

This filing

the headcount reduction, which are expected to be realized beginning in January 2026. Semler Scientific currently estimates that it will incur severance costs of approximately $1.2 million consisting of one-time termination benefits, which are expected to be paid in December 2025 and January 2026. The charges Semler Scientific expects to incur in connection with

Comparable filing

On April 2, 2026, the Company initiated a workforce reduction, which it expects to be completed by mid-year 2026, that will impact up to 5% of its employees. The reduction is part of a broader effort to optimize the Company’s cost structure. The Company expects to incur restructuring charges of approximately $0.2 million, primarily for severance and related costs, in the second quarter of 2026.